Associate Professor
Massachusetts General Hospital
Motaz Qadan, MD, PhD, is a hepatobiliary and pancreatic surgical oncologist at the Massachusetts General Hospital. Dr. Qadan received his undergraduate and medical degrees from the University of Edinburgh Medical School. He completed surgical residency at Stanford University. Following this, he completed a fellowship in complex general surgical oncology at the Memorial Sloan Kettering Cancer Center in New York. Dr. Qadan's leadership positions include Complex General Surgical Oncology Fellowship Program Director at the MGH, Harvard Medical Student Advanced Surgical Clerkship Director, Director of Hepatic Arterial Pump Program, Clinical Lead for Enhanced Recovery after Surgery (ERAS) in Pancreas Surgery, Pancreas Cyst Clinic Director, Hepatobiliary Surgery Director for Young Adult Colorectal Cancer Center, and Mass General Brigham Resident and Fellow Wellbeing Council Faculty Advisor. The Qadan laboratory focuses on the tumor microenvironment in pancreas cancer. Current scientific and translational efforts in his laboratory include the evaluation of the radiosensitizing effects of Losartan and introduction of Fingolimod (sphingosine-1-phosphate receptor 1 antagonist) for endothelial barrier disruption in orthotopic pancreatic tumor models. Dr. Qadan is also interested in clinical outcomes health services research and leads a large group of researchers who focus on methods to collect, analyze, and improve outcomes related to cancer surgery at the institutional and national level. Dr. Qadan is an active clinical investigator in several high impact clinical trials. Finally, he is actively involved in many National societies and holds active leadership roles in several organizations. He has over 170 peer-reviewed scientific articles as well as several book chapters and scientific abstracts.